A new and potentially cost-saving method of treating second-degree burns developed by Avita Medical (ASX: AVH) is now undergoing a clinical trial in China.
Avita hopes to see its RECELL treatment receive strong laboratory support following excellent testimonials and feedback received as a result of work done with Huddersfield University in the UK, as well as other research laboratories around the world.
Avita is hopeful that a successful trial will serve as a validator for RECELL’s efficacy and help pave the way for the company to establish a significant presence in the Chinese market.
RECELL is a medical device designed to facilitate skin regeneration while minimising the amount of skin harvested at the time of surgery.
By being able to reduce donor site skin requirements, accelerating the healing process and reducing the amount of tissue rejection, Avita intends to gain a potentially crucial commercial advantage.
If successful, Avita’s RECELL technology could lead to significant improvements in how severe burns are treated, including reduced treatment time, less scarring and better pigmentation after treatment.
Trialling towards better skin regeneration
Avita announced that it has now commenced a randomised and controlled clinical trial of RECELL entitled “Key Technique and Clinical Pathway for Burn Treatment”, to be led by Dr Dahai Hu, with funding obtained from the China National Health and Family Planning Commission.
In parallel to the trial, Avita confirmed that it will also be collaborating with the Plastic Surgery Department of Peking Union Medical College Hospital (PUMCH), to establish a RECELL training centre based in Beijing.
Avita expects that the creation of the training centre will help to create a central hub where physicians and surgeons can be trained in using RECELL on a national scale.
RECELL is being distributed in China by China Pharmaceutical Group Shanghai Medical Instrument Co., a subsidiary of Sinopharm, the state-owned healthcare conglomerate.
“We are pleased to be working with such prestigious organizations as the China National Health and Planning Commission, PUMCH and Sinopharm,” said Dr Michael Perry, CEO of Avita Medical.
“Our initiatives within China are consistent with our evolving strategy of using data from controlled clinical trials and health economic studies to ensure that RECELL is effectively promoted and priced in all major markets,” said Dr Perry.
In addition to today’s news, Avita has also earmarked several clinical trials in burn patients in Australia and the United Kingdom later this year, as well as two controlled clinical trials in the US focusing on paediatric patients.